Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
3.01B | 3.05B | 2.97B | 2.79B | 2.81B | 2.54B | Gross Profit |
1.68B | 1.70B | 1.65B | 1.53B | 1.55B | 1.32B | EBIT |
290.63M | 151.01M | 506.31M | 499.73M | 628.10M | 423.07M | EBITDA |
479.36M | 452.66M | 761.21M | 751.65M | 873.10M | 665.98M | Net Income Common Stockholders |
149.39M | 69.67M | 356.33M | 363.14M | 485.37M | 335.32M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
284.12M | 290.19M | 222.85M | 292.03M | 445.08M | 375.88M | Total Assets |
7.16B | 7.10B | 7.53B | 6.93B | 6.87B | 7.15B | Total Debt |
2.00B | 1.76B | 1.93B | 1.83B | 1.97B | 2.56B | Net Debt |
1.72B | 1.46B | 1.70B | 1.54B | 1.52B | 2.19B | Total Liabilities |
3.07B | 2.82B | 3.09B | 2.91B | 3.12B | 3.82B | Stockholders Equity |
4.10B | 4.28B | 4.44B | 4.02B | 3.75B | 3.34B |
Cash Flow | Free Cash Flow | ||||
479.84M | 509.31M | 419.20M | 262.95M | 579.80M | 345.71M | Operating Cash Flow |
597.85M | 635.74M | 510.64M | 342.14M | 651.42M | 436.41M | Investing Cash Flow |
-103.34M | -99.36M | -621.23M | -257.94M | 156.74M | -837.78M | Financing Cash Flow |
-350.48M | -421.93M | 38.54M | -217.51M | -715.82M | 455.16M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
76 Outperform | $5.84B | 47.32 | 9.16% | ― | 8.24% | 18.54% | |
69 Neutral | $3.46B | 20.18 | 18.83% | ― | 8.14% | 2.55% | |
68 Neutral | $3.32B | ― | -4.62% | ― | 7.19% | -56.19% | |
58 Neutral | $5.61B | 39.98 | 3.48% | 1.07% | 0.29% | -48.98% | |
57 Neutral | $4.15B | ― | -5.56% | ― | 11.94% | -6.98% | |
56 Neutral | $7.17B | ― | -1.16% | ― | 4.88% | -196.93% | |
53 Neutral | $5.24B | 3.07 | -43.58% | 2.80% | 16.87% | -0.11% |
On May 9, 2025, Teleflex Incorporated’s Board of Directors approved amendments to the company’s bylaws, specifically removing a section that required stockholder actions to occur only at official meetings. This change could impact how stockholder decisions are made in the future. Additionally, during the 2025 annual meeting, stockholders voted on various proposals, including the election of directors and executive compensation, with most proposals receiving majority approval, except for a stockholder proposal on special meeting requirements.
The most recent analyst rating on (TFX) stock is a Buy with a $285.00 price target. To see the full list of analyst forecasts on Teleflex stock, see the TFX Stock Forecast page.
Teleflex reported a decrease in first-quarter revenues for 2025, with a 5.0% decline compared to the previous year, and adjusted diluted EPS also fell from $3.21 to $2.91. Despite these challenges, the company raised its full-year revenue growth outlook on a GAAP basis and completed a $300 million accelerated share repurchase. Teleflex is also exploring the separation into two independent companies, which has attracted significant third-party interest. The company is working on strategies to mitigate the impact of tariffs, which are expected to cost approximately $55 million in 2025.
On February 24, 2025, Teleflex amended its credit agreement to facilitate a $500 million delayed draw term loan for acquiring BIOTRONIK’s Vascular Intervention business, enhancing its product suite in coronary and peripheral interventions. Additionally, the company announced the retirement of CFO Thomas E. Powell and the appointment of John R. Deren as his successor, effective April 2, 2025, alongside strategic plans to separate into two publicly traded entities, aiming to streamline operations and increase management focus.